IN THE CLAIMS

This is a complete and current listing of the claims, marked with status identifiers in parentheses. The following listing of claims will replace all prior versions and listings of claims in the application.

- 2. (Currently Amended) Method according to claim 1, wherein the <u>at least one of the homopolymer and/or copolymer of 1,3-trimethylene carbonate (TMC) is/are-characterized by includes a number average molecular weight (M_n) greater than 10,000, preferably between 10,000 to 300,000, and more preferably between 50,000 to 200,000.</u>
- 3. (Currently Amended) Method according to claim 1—or claim 2, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is chosen from the group consisting of 1,3-trimethylene carbonate (TMC) (co)polymers with lactones—(cyclic esters), cyclic carbonates, cyclic ethers, cyclic anhydrides, and cyclic depsipeptides—(morpholine 2,5 dione derivatives).
- 4. (Currently Amended) Method according to any of the claims 1 3claim 1, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is chosen from the group consisting of a statistical copolymer, a random copolymer, an alternating copolymer, a block polymer, a diblock copolymer, a triblock

copolymer, a multiblock copolymer, a star-shaped block copolymer, and a graft block copolymer.

- 5. (Currently Amended) Method according to any of the claims 1 4claim 1, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is chosen from the group consisting of 1,3-trimethylene carbonate (TMC) (co)polymers with polyethylene oxide (PEO), polyethylene glycol (PEG) and ,-caprolactone (CL).
- 6. (Currently Amended) Method according to <u>claim lany</u> of the claims 1-5, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is chosen from the group consisting of 1,3-trimethylene carbonate (TMC) (co)polymers with *-valerolacton, 1,5-dioxepane-2-one, and ,-caprolactone.
- 7. (Currently Amended) Method according to <u>claim lany</u> of the claims 1 6, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is poly(1,3,-trimethylene carbonate-co-,-caprolactone) (poly(TMC-CL)).
- 8. (Currently Amended) Method according to any <u>claim</u>

 <u>1of the claims 1-7</u>, wherein the actinic radiation is chosen from the group consisting of gamma radiation, high-energy UV radiation and electron radiation, preferably gamma radiation.
- 9. (Currently Amended) Method according to claim $\frac{1}{2}$ of the claims 1-8, wherein the actinic radiation is gamma radiation and the irradiation dosage is 5-100 kGy, preferably $\frac{10-45 \text{ kGy}}{2}$.
- 10. (Currently Amended) Method according to claim 1 any of the claims 1 -9, wherein the inert atmosphere is obtained by means use of a reduced pressure of less than 10^4 Pa.

- 11. (Currently Amended) Method according to <u>claim lany</u> of the claims 1 10, wherein the inert atmosphere is obtained by <u>means_use</u> of an inert gas, <u>preferably nitrogen</u>.
- 12. (Currently Amended) Method according to any of the claims 1 11claim 1, characterized by wherein a creep rate of the provided shaped biodegradable elastomeric structure of is less than 10% of the yield stress.
- 13. (Currently Amended) Method according to any of the claims 1 12claim 1, characterized by wherein a degree of swelling of the provided shaped biodegradable elastomeric structure of is less than 400% in chloroform.
- 14. (Currently Amended) Method according to any of the claims 1 13claim 1, characterized by wherein a gel fraction of the provided shaped biodegradable elastomeric structure of is more than 10% by weight.
- 15. (Currently Amended) Method according to any of the claims 1 14claim 1, further comprising sterilization of sterilizing the provided shaped biodegradable elastomeric structure, preferably in an autoclave.
- 16. (Currently Amended) Shaped biodegradable elastomeric structure obtainable by a method according to any of the claims 1 15claim 1.
- 17. (Currently Amended) A method, comprising:

 using Use of a shaped biodegradable elastomeric structure according to claim 16 in or as at least one of an implant, and/or a matrix and/or a support device.
- 18. (Currently Amended) <u>A Medical medical implant,</u> and/or matrix and/or support device comprising:

-a shaped biodegradable elastomeric structure according to claim 16.

- 19. (New) Method according to claim 1, wherein the at least one of the homopolymer and copolymer of 1,3-trimethylene carbonate (TMC) includes a number average molecular weight $(M_{\rm n})$ between 10,000 to 300,000.
- 20. (New) Method according to claim 1, wherein the at least one of the homopolymer and copolymer of 1,3-trimethylene carbonate (TMC) includes a number average molecular weight (M_n) between 50,000 to 200,000.
- 21. (New) Method according to claim 1, wherein the actinic radiation is gamma radiation and the irradiation dosage is $10-45~\mathrm{kGy}$.
- 22. (New) Method according to claim 1, wherein the sterilizing of the provided shaped biodegradable elastomeric structure is done in an autoclave.
 - 23. (New) A matrix, comprising:
- a shaped biodegradable elastomeric structure according to claim 16.
 - 24. (New) A support device, comprising:
- a shaped biodegradable elastomeric structure according to claim 16.